Detalhe da pesquisa
1.
Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats.
Am J Physiol Renal Physiol
; 320(1): F133-F144, 2021 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33283643
2.
Metabolism and pharmacokinetics of naronapride (ATI-7505), a serotonin 5-HT(4) receptor agonist for gastrointestinal motility disorders.
Drug Metab Dispos
; 39(7): 1170-80, 2011 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-21447732
3.
Evaluation of the Pharmacodynamic Effects of the Potassium Binder RDX7675 in Mice.
J Cardiovasc Pharmacol Ther
; 23(3): 244-253, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29130735
4.
An Evaluation of the Pharmacodynamics, Safety, and Tolerability of the Potassium Binder RDX7675.
J Clin Pharmacol
; 58(8): 1035-1043, 2018 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-29645278
5.
Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability.
Sci Transl Med
; 10(456)2018 08 29.
Artigo
Inglês
| MEDLINE | ID: mdl-30158152
6.
Development and Characterization of a Human and Mouse Intestinal Epithelial Cell Monolayer Platform.
Stem Cell Reports
; 9(6): 1976-1990, 2017 12 12.
Artigo
Inglês
| MEDLINE | ID: mdl-29153987
7.
Quinazolinone fungal efflux pump inhibitors. Part 3: (N-methyl)piperazine variants and pharmacokinetic optimization.
Bioorg Med Chem Lett
; 17(10): 2802-6, 2007 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-17350259